In summary, our findings affirm that the reduction of HCP5‐132aa levels in vivo can induce ferroptosis and thereby inhibit tumor growth in GC, suggesting that HCP5‐132aa may be a promising therapeutic target for GC (Figure 8). Here, HCP5 is linked to gastric cancer.